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Angiopoietin-2 attenuates 
angiotensin II-induced aortic 
aneurysm and atherosclerosis in 
apolipoprotein E-deficient mice
Hongyou Yu1,*, Corey S. Moran1,*, Alexandra F. Trollope2,*, Lynn Woodward1, Robert Kinobe3, 
Catherine M. Rush3 & Jonathan Golledge1,4
Angiogenesis and inflammation are implicated in aortic aneurysm and atherosclerosis and regulated 
by angiopoietin-2 (Angpt2). The effect of Angpt2 administration on experimental aortic aneurysm 
and atherosclerosis was examined. Six-month-old male apolipoprotein E deficient (ApoE−/−) mice 
were infused with angiotensin II (AngII) and administered subcutaneous human Fc-protein (control) or 
recombinant Angpt2 (rAngpt2) over 14 days. Administration of rAngpt2 significantly inhibited AngII-
induced aortic dilatation and rupture of the suprarenal aorta (SRA), and development of atherosclerosis 
within the aortic arch. These effects were blood pressure and plasma lipoprotein independent and 
associated with Tie2 activation and down-regulation of monocyte chemotactic protein-1 (MCP-1) within 
the SRA. Plasma concentrations of MCP-1 and interleukin-6 were significantly lower in mice receiving 
rAngpt2. Immunostaining for the monocyte/macrophage marker MOMA-2 and the angiogenesis marker 
CD31 within the SRA were less in mice receiving rAngpt2 than controls. The percentage of inflammatory 
(Ly6Chi) monocytes within the bone marrow was increased while that in peripheral blood was decreased 
by rAngpt2 administration. In conclusion, administration of rAngpt2 attenuated angiotensin II-induced 
aortic aneurysm and atherosclerosis in ApoE−/− mice associated with reduced aortic inflammation and 
angiogenesis. Up-regulation of Angpt2 may have potential therapeutic value in patients with aortic 
aneurysm and atherosclerosis.
Abdominal aortic aneurysm (AAA) is an abnormal dilatation of the abdominal aorta affecting 2–5% of men aged 
over 65 years that can lead to life-threatening aortic rupture1. Intensive investigation over the last two decades 
has not yet led to discovery of a drug-based therapy to limit AAA growth2. The pathogenesis of AAA is a complex 
process involving inflammation, extracellular matrix remodelling and angiogenesis1. Atherosclerosis is a usual 
finding in biopsies of end-stage AAA. Athero-thrombosis is also a recognised risk factor for AAA1. Nevertheless, 
it is still unknown whether atherosclerosis is causative for AAA or whether the association simply reflects com-
mon risk factors3,4.
Inflammation and extracellular matrix degradation provide a pro-angiogenic environment conducive to 
neo-vessel formation5. Angiogenesis is believed to promote AAA and atherosclerosis development and progres-
sion through encouraging extracellular matrix remodelling and facilitating inflammatory cell infiltration1,6,7. 
AAA rupture is associated with neovascularization8. A higher density of micro-vessels has been reported in biop-
sies from ruptured than intact AAAs9.
Angiopoietin-2 (Angpt2) is a well-studied member of a family of vascular growth factors known to reg-
ulate angiogenesis10. Angpt2 was originally identified by virtue of its ability to interfere with the action of 
angiopoietin-1 through competition for the receptor Tie211. Transgenic mice over expressing Angpt2 have dis-
rupted vessel formation that is similar but more severe than mice with deficiency of angiopoietin-1 or Tie212. In 
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humans, increased serum Angpt2 is associated with AAA prevalence and cardiovascular mortality in older men13, 
however, a direct role for Angpt2 in AAA remains unclear.
Given the significance of angiogenesis and inflammation in AAA and atherosclerosis, we hypothesised that 
Angpt2 would be important in the development of AAA and atherosclerosis and examined this in the angiotensin 
II (AngII)-infused Apolipoprotein E deficient (ApoE−/−) mouse model.
Results
Administration of rAngpt2 reduced aortic aneurysm development in response to AngII infusion. 
A total of 50 6-month-old male ApoE−/− mice were infused with angiotensin II (AngII) for 14 days. Mice received 
rAngpt2 (n = 25) or human Fc protein (control; n = 25) at a dose 4 mg/kg every other day commencing 24 hours 
prior to AngII infusion. Two mice in the control group and one mouse in the rAngpt2 group died during the 
experimental period of non-aneurysm related causes and were excluded from the study. Aortic rupture occurred 
in 4 out of the 23 control mice (17%) at days 5, 6, 12 and 13. There were no aortic ruptures in mice receiving 
rAngpt2 (P = 0.045, Fisher’s exact test). Accordingly, intervention improved survival from aortic rupture from 
83% in control mice to 100% in mice receiving rAngpt2 (P = 0.034; Fig. 1A). The response to AngII infusion 
ranged from focal dilatations of the suprarenal aorta (SRA) to complex dissection throughout the vessel (see 
Figure 1. Effect of rAngpt2 on AngII-induced aortic dilatation and atherosclerosis in ApoE−/−mice. 
(A) Kaplan-Meier curves of survival free of aneurysm rupture in AngII-infused ApoE−/− mice administered 
rAngpt2 (○ ; 4.0 mg/kg/48 hrs, s.c.) or control peptide (• ); *P = 0.034 compared to controls using Log-rank 
(Mantel-Cox) test. (B) Regional aortic diameters for AngII-infused ApoE−/− mice administered rAngpt2 (white; 
4.0 mg/kg/48 hrs, s.c.; n = 24) or control peptide (grey; n = 23) determined by morphometry at sacrifice (day 
14). Data expressed as median and interquartile range with maximum and minimum data points (whiskers) for 
maximum diameters (mm) and compared by Mann-Whitney U test. TA, thoracic aorta; SRA, suprarenal aorta; 
IRA, infrarenal aorta. (C) Sudan IV staining area within the aortic arch of mice receiving rAngpt2 (4.0 mg/
kg/48 hrs, s.c.; n = 24) compared to controls (n = 19). Data expressed as mean ± SEM for positive staining area 
relative to total specimen area (%); *P = 0.017 compared by unpaired-t test. (D) Atherosclerotic plaque within 
the brachiocephalic artery (BCA) of mice receiving rAngpt2 (4.0 mg/kg/48 hrs, s.c.; n = 8) compared to controls 
(n = 7). Data expressed as median and interquartile range with maximum and minimum data points (whiskers) 
for plaque cross-sectional area relative to total luminal area (%); *P = 0.009 compared by Mann-Whitney U test.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:35190 | DOI: 10.1038/srep35190
Supplementary Fig. S1). The severity of aortic response to AngII was scored using a scale based upon gross 
appearance as previously described (Table 1)14. Quantitative morphometric analysis of the aortas of the mice 
demonstrated significantly smaller mean maximum SRA diameter in mice receiving rAngpt2 than control 
(P = 0.002, Fig. 1B). Smaller diameters of the aortic arch, thoracic (TA) and infrarenal aorta (IRA) were also 
observed in mice receiving rAngpt2 although differences were not statistically significant compared to controls 
(Fig. 1B). rAngpt2 administration did not influence AngII-induced elevation of blood pressure (Table 2).
Atherosclerosis within the aortic arch was reduced in mice administered rAngpt2. AngII infu-
sion accelerates atherosclerosis development in ApoE−/− mice particularly within the aortic arch6,15. Intimal ath-
eroma within the aortic arch and plaque development within the brachiocephalic artery (BCA) of surviving mice 
was assessed by Sudan IV staining and Haematoxylin and Eosin histology, respectively. Mean positive Sudan 
IV staining area within the aortic arch was reduced from 41.15 ± 4.99% in control mice to 27.87 ± 2.63% in 
mice receiving rAngpt2 (P = 0.017; Fig. 1C; Supplementary Fig. S2). Similarly, the median cross-sectional plaque 
area within the BCA was reduced 3-fold in mice administered rAngpt2 compared to control (P = 0.009; Fig. 1D; 
Supplementary Fig. S3). Circulating lipid profile was similar in the intervention and control groups (Table 2).
AngII-induced aortic inflammation was reduced in mice administered rAngpt2. Angpt2 can 
sensitise endothelial cells to inflammatory stimuli through the regulation of Tie211,16. Western blotting was used 
to determine phosphorylated Tie2/total Tie2, nuclear (NFκ B) p65/PCNA, and MCP-1 protein levels within 
SRA tissue (Fig. 2A). Tie2 phosphorylation was up-regulated within the aortic tissue of mice receiving rAngpt2 
(P = 0.004; Fig. 2B). Mice receiving rAngpt2 had lower SRA levels of nuclear p65 compared with controls, 
although the difference was not statistically significant (P = 0.093; Fig. 2C). Expression of monocyte chemot-
actic protein (MCP)-1 within SRA tissue was positively correlated with maximum SRA diameter (r2 = 0.781; 
P = 0.043). Median aortic MCP-1 concentration was markedly reduced in mice administered rAngpt2 compared 
to controls (P = 0.004; Fig. 2D). Immunostaining area for monocyte/macrophages (MOMA-2) in SRA sections 
was significantly reduced in mice administered rAngpt2 compared to controls (P = 0.004; Fig. 3A upper panel & 
3B). Angiogenesis was assessed in SRA tissue obtained at the end of experiments by immunostaining for CD31 
and ELISA for VEGF. Both intimal and adventitial micro-vessel endothelial cells were positively stained for CD31 
(Fig. 3A lower panel). rAngpt2 administration was associated with a lower median CD31-positive staining area 
within the SRA adventitia (P = 0.002; Fig. 3C). Mice receiving rAngpt2 had similar median aortic VEGF concen-
tration as controls (Fig. 3D).
rAngpt2 administration affected circulating profile of Ly6Chi monocytes. At completion of the 
AngII infusion period, median plasma concentrations of MCP-1 and interleukin-6 were 3- and 4-fold lower, 
Group n Type 0 Type I Type II Type III Type IV
Control 23 3 5 0 5 10
rAngpt2 24 5 14 1 0 4
Table 1.  Visual classification of aortic aneurysms formed in response to AngII. Type 0, no dilatation; Type 
I, dilatation of the aorta with no thrombus; Type II, dilatation of the aorta containing thrombus; Type III, a 
pronounced bulbous form of Type II; Type IV, multiple, complex form of Type III.
Day
Control 
(n = 7)
rAngpt2 
(n = 10) P
BP (mmHg)
SBP
0 97 (93–101) 100 (94–104) 0.361
14 132 (98–163)* 123 (111–134)* 0.706
DBP
0 76 (74–80) 80 (76–85) 0.108
14 105 (79–137)* 96 (85–122)* 0.690
MBP
0 83 (80–86) 88 (79–91) 0.184
14 114 (85–145)* 104 (94–132)* 0.706
Cholesterol (μ g/μ l)
Total
0 4.4 (3.9–5.8) 3.9 (3.5–4.9) 0.297
14 4.3 (3.2–4.6) 3.4 (2.9–4.0) 0.229
HDL fraction
0 2.4 (2.1–3.1) 2.6 (1.3–3.6) 0.600
14 2.5 (1.7–3.0) 1.9 (1.3–2.4) 0.133
LDL/VLDL fraction
0 2.1 (1.3–2.9) 2.0 (1.3–2.4) 0.402
14 1.1 (1.5–1.7) 1.2 (1.6–2.1) 0.516
Table 2.  Blood pressure and plasma lipids in AngII-infused ApoE−/− mice at baseline (Day 0) and 14-
days post administration of rAngpt2 or control. Data expressed as median (interquartile range); rAngpt2, 
recombinant angiopoietin 2; P, p-value for comparison between groups by Mann-Whitney U test; *P < 0.05 
compared to Day 0; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, 
mean blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density 
lipoprotein.
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respectively, in mice receiving rAngpt2 compared to controls (Fig. 4A; P = 0.010 and 0.013, respectively). There 
was no significant difference between median plasma tumour necrosis factor concentrations in mice receiving 
rAngpt2 and those injected with control protein (3.68, 3.41–6.84 pg/ml versus 4.49, 3.21–8.34 pg/ml, respectively; 
P = 0.794, n = 6). IFN-γ and IL-12p50 were not detectable in the plasma of either group. Mice administered 
rAngpt2 had lower median levels of circulating inflammatory (CD11b+Ly6G-Ly6Chi) monocytes compared to 
control animals (P = 0.019; Fig. 4B), but a significantly higher median percentage of inflammatory monocytes 
within the bone marrow (P = 0.019; Fig. 4C). The median percentage of inflammatory monocytes in the spleen 
was similar in the two groups (P = 0.516; Fig. 4D). A very low mean percentage of the total circulating leuko-
cyte population (~0.5%) in blood of mice prior to AngII infusion (baseline) was identified as Tie2-expressing 
(CD11b+Tie2+). The mean percentage of circulating CD11b+Tie2+ cells following 14 days of AngII infusion 
remained similar to baseline (P > 0.05; Supplementary Fig. S4).
Discussion
This study investigated the effect of Angpt2 on AAA development and atherosclerosis in the ApoE−/− mouse 
model. Systemic administration of rAngpt2 attenuated AngII-induced AAA formation and atherosclerosis pro-
gression. Examination of aortic tissue showed that aortic monocyte/macrophage infiltration, aortic concentra-
tion of MCP-1, and aortic neo-vascularisation was reduced in mice receiving rAngpt2. In addition, these mice 
exhibited lower percentage of circulating Ly6Chi (inflammatory) monocytes that corresponded with reduced con-
centration of plasma MCP-1. We have reported previously that serum Angpt2 is elevated in men with AAA and 
associated with an increased risk of cardiovascular mortality in this population13, although whether this was cause 
or consequence remained unclear. Here we provide in vivo evidence supporting a protective role for Angpt2 in 
experimental AAA and atherosclerosis.
Figure 2. Effect of rAngpt2 on Tie2 phosphorylation and inflammation markers within the suprarenal 
aorta. (A) Representative western blots for Tie2/phosphorylated Tie2Tyr992, nuclear (NFκ B) p65/PCNA, and 
MCP-1. Tie2Tyr992 phosphorylation (B), nuclear p65 (C), and MCP-1 (D) levels within the SRA of AngII-infused 
ApoE−/− mice administered rAngpt2 (4.0 mg/kg/48 hrs, s.c.; n = 6) or controls (n = 6) after 14 days. Data 
expressed as median and interquartile range with maximum and minimum data points (whiskers) for relative 
density units (RDU) per microgram (μ g) protein, compared by Mann-Whitney U test.
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Angiopoietin-Tie signalling is an important regulator of vascular homeostasis, angiogenesis, and inflamma-
tion10,17. Tie2 is activated in order to maintain the quiescent state of the vasculature14 whereas Tie2 is deactivated 
in the process of angiogenesis and inflammation16,18,19. Therefore, Tie2 activation is important in maintaining 
the integrity of the endothelium of the aorta. Angpt2, unlike angiopoietin-1, has a complex role and dynamically 
regulates Tie2 in a context dependent manner20,21. Angpt2 is mainly expressed by endothelial cells and stored 
in intracellular granules that can be released rapidly to de-activate Tie2 in an autocrine manner in response to 
inflammatory and angiogenic stimuli21. In contrast exogenously administered Angpt2 has been demonstrated to 
activate Tie2 and limit angiogenesis both in vivo and in vitro20,22–25. Moreover, it has been reported that exogenous 
Angpt2 administration inhibited leukocyte infiltration in the presence of inflammatory stimuli22,26. In the current 
study, we report that exogenous rAngpt2 administration induced Tie2 activation and reduced monocyte/mac-
rophage infiltration within the aortic wall in the presence of AngII, an important regulator of the inflammatory 
response27.
Angpt2 has critical roles in angiogenesis. It has been reported that up-regulation of Angpt2 in animal mod-
els of cancer disrupted tumour vasculature10,23–25. In the current study we found that mice receiving systemic 
administration of rAngpt2 had lower aortic staining for the angiogenesis marker CD31 than controls. There is 
evidence that AAA and atherosclerosis are associated with excessive angiogenesis in both patients and animal 
models8,9,28,29. Indeed, anti-angiogenic interventions have been shown to attenuate experimental AAA28,30. 
Figure 3. Effect of rAngpt2 on monocyte/macrophage infiltration and markers of angiogenesis within 
the suprarenal aorta. (A) Immunostaining for macrophages (arrow) and angiogenesis with MOMA-2 
(upper panel) and CD31 (lower panel), respectively. Response to AngII after 14 days in SRA of ApoE−/− mice 
administered rAngpt2 (4.0 mg/kg/48 hrs, s.c.; n = 6) or control (n = 6). L, lumen; cell nuclei stained blue; 200x 
magnification; scale bar, 50 μ m; negative is isotype IgG control and represents background fluorescence. Data 
for MOMA-2 (B) and CD31 (C) expressed as median and interquartile range with maximum and minimum 
data points (whiskers) for positive staining area relative to total specimen area (%); *P < 0.01 compared by 
Mann-Whitney U test. (D) Concentration of VEGF within the SRA of mice receiving rAngpt2 (4.0 mg/
kg/48 hrs, s.c.; n = 6) compared to controls (n = 6). Data expressed as median and interquartile range with 
maximum and minimum data points (whiskers) for picograms (pg) of VEGF per μ g protein, compared by 
Mann-Whitney U test.
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Prolonged exposure of endothelial cells to Angpt2 induces apoptosis and vessel regression in the absence of 
VEGF12,31,32. In line with this, we found that reduced AAA development in mice administered Angpt2 was asso-
ciated with decreased aortic expression of CD31, with no change in aortic tissue level of VEGF. Tie2-expressing 
monocytes/macrophages have been shown to be proangiogenic in some animal models33,34. However, it is not 
likely that Tie2-expressing monocytes/macrophages play an important role in the findings of the current study 
since mice receiving rAngpt2 had less micro-vessel formation within the aorta. Moreover, Tie-2-expressing 
monocytes/macrophages were barely detectable in blood of ApoE−/− mice prior to (baseline) and after the AngII 
infusion period.
The extent of angiogenesis correlates with the severity of inflammatory cell infiltration in AAA biopsies9,35. 
AngII induced AAA and atherosclerosis have been associated with aortic macrophage accumulation6,36. Such 
aortic inflammation may in part be a consequence of AngII induced angiogenesis since newly formed patholog-
ical capillaries are normally poorly organised and highly permeable37. Furthermore, infusion of AngII promotes 
NF-κ B activation and up-regulation of aortic MCP-1 expression, which are effects that are closely associated 
with aortic aneurysm progression and rupture27,38–41. In addition to our observation that rAngpt2 administration 
reduced markers of angiogenesis we also demonstrated less aortic macrophage staining and MCP-1 expression in 
mice that received rAngpt2. Maximum aortic diameter is commonly presented as the primary outcome measure 
in experimental AAA studies36,42,43. AAA diameter is an important clinical indicator of rupture risk and routinely 
used in selecting patients for surgical intervention44. Ultimately any medical treatment for aortic aneurysm aims 
to limit AAA rupture. We utilised the AngII-infused ApoE−/− mouse model of aortic aneurysm in which aortic 
dilatation results from breaks in medial elastic lamellae, bleeding into the artery wall and aortic wall inflam-
mation, a process that leads to acute aortic rupture in approximately 30% of mice36,45. This model allowed the 
Figure 4. Effect of rAngpt2 on blood and tissue profile of Ly6C-positive inflammatory monocytes.  
(A) Circulating concentration of MCP-1 and IL-6 in AngII-infused mice receiving rAngpt2 (4.0 mg/kg/48 hrs, 
s.c.; n = 6) or control peptide (n = 6) after 14 days. Data expressed as median and interquartile range with 
maximum and minimum data points (whiskers) for picograms (pg) of protein per ml plasma; *P = 0.010  
and †P = 0.013 compared by Mann-Whitney U test. Inflammatory (Ly6Chi) monocytes within the circulation 
(B), bone marrow (C), and spleen (D) of AngII-infused mice receiving rAngpt2 (4.0 mg/kg/48 hrs, s.c.; n = 10) 
or control peptide (n = 7) after 14 days. Data expressed as median and interquartile range with maximum 
and minimum data points (whiskers) for CD11b+Ly6G-Ly6Chi cells relative to total leukocyte population (%); 
*P = 0.019 (B,C) compared by Mann-Whitney U test.
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assessment of both survival free from aortic rupture and maximum aortic diameter. Administration of Angpt2 
limited AngII-induced aortic dilatation and protected against aortic rupture.
Ly6Chi inflammatory monocytes express C-C chemokine receptor type 2 (CCR2), a receptor for MCP-1. 
Markedly reduced aortic dilatation46 and plaque formation47 in CCR2-deficient mice suggests the importance of 
CCR2-MCP-1 signalling in AAA and atherosclerosis development in rodent models. CCR2-MCP-1 signalling 
controls Ly6Chi inflammatory monocyte egress from the bone marrow to the circulating blood and recruitment 
to inflammatory sites, where they differentiate into activated macrophages39. Inflammatory monocytes have been 
implicated in the pathogenesis of AAA and atherosclerosis48–50. We found less inflammatory monocytes within 
the circulation of mice receiving rAngpt2 at day 14 of our experiment when the plasma concentration of MCP-1 
was significantly less than control mice. We also found a higher percentage of Ly6Chi cells within the bone mar-
row of mice receiving rAngpt2. These findings suggested that rAngpt2 administration restricted inflammatory 
monocyte egress from the bone marrow.
The effect of Angpt2 on AAA and atherosclerosis has not previously been investigated in the AngII-infused 
AAA mouse model. We used systemic administration of rAngpt2 which is relevant to situations where angi-
ogenesis is being therapeutically targeted by intravenous agents51. In a recent clinical trial, for instance, the 
anti-angiogenic agent bevacizumab, a humanized monoclonal antibody neutralising VEGF activity, was admin-
istered intravenously in order to limit cancer progression54. Our results are consistent with other studies in which 
systemic Angpt2 administration has been shown to stimulate regression of neovascularisation10,23,24 and a previ-
ous study in which up-regulation of Angpt2 by systemic administration of an adenovirus vector inhibited ather-
osclerosis progression by 40%52.
The current study has a number of limitations. Firstly, rAngpt2 administration was associated with reduction 
in both AAA and atherosclerosis. Thus it is possible that the reduction in atherosclerosis may have caused a sec-
ondary reduction in AAA. The role of atherosclerosis in AAA is controversial and it is not likely that atheroscle-
rosis is the primary cause of AAA in the model used in the current study thus we think this is unlikely4. Secondly, 
since Angpt2 has many actions the precise mechanism by which rAngpt2 limited AAA and atherosclerosis in 
our study is not certain. Angpt2 is needed for functional lymphatics as mice deficient in Angpt2 show defective 
lymphatic patterning53. However, we did not assess lymphatics in the current study.
In summary, the current study suggests that rAngpt2 administration limits AAA and atherosclerosis in a 
mouse model associated with reduced angiogenesis and inflammation. These results suggest the potential ben-
eficial functions of rAngpt2 administration in cardiovascular disease and provide a possible strategy for AAA 
prevention and treatment.
Methods
Recombinant angiopoietin-2 and control human Fc protein. Recombinant human angiopoietin-2 
(rAngpt2) and control human Fc protein were kindly provided by Regeneron Pharmaceuticals (Tarrytown, NY, 
USA). The rAngpt2 used in this study is equivalent to AngF2-Fc-F2 described in detail in previous publications54.
Mouse studies. The use of animals for this work conformed to the Guide for the Care and Use of Laboratory 
Animals (National Institutes of Health, USA). Approval for the mouse studies and experimental work performed 
was obtained from and in accordance with the James Cook University Animal Ethics Committee (A1671). Six 
month old male ApoE−/− mice were obtained from the Animal Resources Centre (Canning Vale, Australia). 
Mice were housed in an individually-ventilated, temperature/humidity-controlled cage system (Aero IVC Green 
Line; Tecniplast) on a 12-hour light/dark cycle, and maintained on normal laboratory chow and water ad libitum. 
ApoE−/− mice were allocated to receive rAngpt2 or control peptide. The planned primary outcome measure 
was SRA diameter, as this is the main site of aneurysm formation in the mouse model employed6,36. Based on a 
previous study it was estimated that a sample size of 20 mice per group would have at least 80% power to detect a 
25% difference in SRA diameter (alpha 0.05)55. In order to allow for potential dropouts due to mice fatalities we 
included 25 mice in each group. All of these mice were also used to assess survival free from aneurysm rupture 
and atherosclerosis lesion area in the aortic arch. The other secondary outcomes in this study were assessed in 
one subset experiment (n = 10 in each group) and included blood pressure; plasma lipids; aortic and plasma 
concentration of pro-inflammatory cytokines; peripheral blood, bone marrow and spleen levels of inflammatory 
monocytes; monocyte/macrophage infiltration of the aortic wall; and angiogenesis within the aortic wall.
Angiotensin II induced AAA model and administration of rAngpt2. All mice received 1.44 mg/kg/
day of AngII (Sigma-Aldrich) via subcutaneous osmotic mini-pumps (Model 1004, ALZET) for 14 days as pre-
viously described56. In brief, mice were anaesthetized by intra-peritoneal injection of ketamine (150 mg/kg) and 
xylazine (10 mg/kg), and then osmotic mini-pumps containing AngII dissolved in sterile water were inserted into 
the subcutaneous space along the left dorsal midline. rAngpt2 or control peptide-Fc fusion protein was admin-
istered subcutaneously every other day at a dose of 4 mg/kg starting the day before AngII infusion commenced.
Tissue collection. Mice were euthanised by CO2 asphyxiation at the completion of the experiment. The 
aorta was exposed under a dissection microscope (Leica). Blood was collected into lithium heparin coated tubes 
(BD Bioscience) from the right ventricle and centrifuged to collect plasma that was stored at − 80 °C for future 
assessment. The aorta was carefully flushed with phosphate buffered saline (PBS) through the left ventricle and 
harvested free from fat and connective tissue. The whole dissected aorta was digitally photographed (Coolpix 
4500, Nikon) on a graduated template44. Then aortic tissues were snap frozen in Optimal Cutting Temperature 
compound and stored at − 80 °C for future analysis. Mice that died prior to completion of the experimental period 
were subject to post-mortem and aortas were harvested for subsequent aortic diameter measurement. Rupture 
was confirmed by intra-thoracic, intra-abdominal or retro-peritoneal blood.
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Measurement of aortic diameters. Maximum diameters of the following aortic regions were measured 
in harvested aortas using established techniques: aortic arch (from aortic valve to left subclavian artery), thoracic 
aorta (from the end of the arch to the diaphragm), SRA (from the diaphragm to the renal arteries), and infrarenal 
aorta (from the renal arteries to bifurcation of the iliac arteries). Maximum diameter of each aortic region was 
determined using Adobe Photoshop CS5 software (V12, Adobe) as previously described43. We have previously 
reported good inter-observer reproducibility of these measurements43,57.
Assessment of atherosclerosis lesion area in the aortic arch. All aortic arches from the mice surviv-
ing to the end of the experiments were used to evaluate the area of intimal atherosclerosis using Sudan IV staining 
as previously described43. In brief, aortic arches were opened longitudinally to expose the intima and pinned on 
wax. Tissues were fixed in 75% ethanol for 15 min followed by staining using Sudan IV solution (0.1% Sudan IV 
dissolved in 1:1 v/v acetone and 70% ethanol) for 10 min. Excess staining solution was removed by a 15 min 80% 
ethanol wash. The stained arch tissues were digitally photographed on a graduated template and the Sudan IV 
staining area was measured using Adobe Photoshop CS5 software (V12, Adobe) as previously described55. We 
have previously reported good inter-observer reproducibility of these measurements43,55.
Non-invasive assessment of blood pressure using a tail-cuff system. Blood pressure was measured 
using a computerised non-invasive tail-cuff system (Kent Scientific, USA) at day 0 (baseline) and day 14 (week 2). 
Mice were acclimatized to the device before measurements. We have previously reported good inter-observer 
reproducibility of these measurements56.
Plasma lipids measurement. Plasma samples, snap frozen and stored at − 80 °C, were used to measure 
circulating lipids using an Abcam high density lipoprotein (HDL) and low and very low density lipoprotein 
(LDL/VLDL) Cholesterol Assay Kit (Abcam) following the manufacturer’s instructions. Briefly, plasma was pre-
cipitated using the provided precipitation buffer followed by centrifugation. The HDL fraction was precipitated 
while low and LDL/VLDL fraction remained in the supernatant. The concentration of cholesterol in each fraction 
was measured using a cholesterol esterase reagent in the reaction buffer. A standard curve was created using the 
provided cholesterol standard. The optical density (OD) value was measured at 570 nm using a micro plate reader 
(BMG Labtech). The concentration of cholesterol in each fraction was determined according to the standard 
curve.
Western blotting. Six SRA tissues were randomly chosen from the rAngpt2 and control groups to 
assess expression of the pro-inflammatory cytokine MCP-1 by Western blotting. Tissues were homogenized 
by three freeze-thaw cycles. Total protein was extracted by sonication with 3–4 bursts of 10 seconds each in 
radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl PH 7.4, 150 mM NaCl; 2 mM EDTA, 1% 
TritonX-100, 0.1% SDS, and 0.1% sodium deoxycholate) in the presence of a protease inhibitor cocktail and 
phosphatase inhibitor (Roche). Nuclear protein was extracted using the NE-PER nuclear protein extraction kit 
(Piercenet). Protein concentration was determined using a Bradford protein assay kit (BioRad). Samples (30 μ g 
of protein per lane) were loaded onto 4–20% Mini-PROTEAN TGX precast polyacrylamide gels (Bio-Rad) and 
were then separated at 110 V for 70 min. Separated proteins were transferred to a polyvinylidene fluoride mem-
brane (BioRad). Non-specific antibody sites were blocked with 5% bovine serum albumin (BSA) for 60 min at 
room temperature. Membranes were probed with primary rat monoclonal anti-monocyte chemotactic protein-1 
(MCP-1; SantaCruz), rabbit polyclonal anti-p65 (Abcam), rabbit polyclonal anti-proliferating cell nuclear antigen 
(PCNA; SantaCruz), mouse monoclonal anti-Tie2 (clone Ab33; Millipore), rabbit polyclonal anti-phosphorylated 
Tie2 (pTie2Tyr992 ; Cell Signaling), or rabbit monoclonal anti-GAPDH (cell Signaling) at a 1:1000 dilution in 2% 
BSA at 4 °C overnight. Anti-rabbit, mouse or rat HRP conjugated IgG (1:2500) (Dako Cytomation) was used as a 
secondary antibody. Blots were developed with Clarity Western ECL Substrate (BioRad) and Image Lab software 
(V5, Bio-rad) was used for densitometry quantification. The data were expressed as relative fold of control by 
normalising the relevant protein’s band intensity to the mean band intensity of the control mice.
Enzyme-linked immunosorbent assay (ELISA). The mouse VEGF Quantikine ELISA kit (R&D) was 
used to assess VEGF protein concentrations in aortic tissue according to the manufacturer’s instructions. In brief, 
30 μ g of protein from the aortic tissue was added to a pre-coated 96-well-plate and incubated at room temperature 
for 2 hours followed by five washes with wash buffer. A polyclonal antibody against mouse VEGF conjugated to 
horseradish peroxidase was added to each well and incubated at room temperature for 2 hours. Then the substrate 
solution was added to each well to incubate at room temperature for 30 min followed by adding stop solution. A 
standard curve was created using the provided standard. The OD value was measured at 450 nm using a micro 
plate reader (BMG Labtech). The concentration of VEGF in each sample was determined according to the stand-
ard curve.
Flow cytometry. At the end of the experiments, peripheral blood was collected via cardiac puncture into 
lithium heparin coated tubes (BD Bioscience). Bone marrow cells were harvested by inserting a 25 gauge needle 
into the left femur and injecting 500 μ l of Dulbecco’s Phosphate Buffered Saline without Ca2+ and Mg2+ (DPBS, 
Gibco) containing 0.2% BSA and 1 mM EDTA (Amresco). Spleens were homogenized in DPBS containing 0.2% 
BSA and 1 mM EDTA and filtered through 60 micron nylon filters. Typically 100 μ l of peripheral blood and 106 
cells from bone marrow or spleen were used for flow cytometry. Cell surface staining for flow cytometry was con-
ducted using standard procedures18. The following monoclonal antibodies were used: anti-CD11b (M1/70)-APC, 
anti-Ly6G (1A8)-PerCP-Cy5.5, anti-Ly6C (AL-21)-FITC (all from BD pharmingen); anti-Tie2 (TEK4)-PE 
(eBioscience). Briefly, erythrocytes were depleted using red blood cell (RBC) lysis buffer (BioLegend) before 
cell suspensions were pre-incubated for 20 min with anti-CD16/32 to prevent the Fc receptors from binding 
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antibodies. Cell suspensions were incubated with staining antibody cocktails for 1 hour at room temperature in 
the dark. Viable leukocytes were identified by forward/side scatter profile and fluorescence-minus-one (FMO) 
controls were used to determine positive and negative boundaries. Inflammatory monocytes were defined as 
CD11b+Ly6G−Ly6Chi. Flow cytometry was performed on a FACSCalibur (BD bioscience) and data were analysed 
with BD CellQuest pro software (v5.1 BD bioscience). Data were expressed as percentage of inflammatory mono-
cytes in total live leukocyte populations.
Assessment of plasma pro-inflammatory cytokines. Cytometric bead array assays (BD Bioscience) 
were used to assess plasma interleukin (IL)-6, IL-12p70, tumour necrosis factor, interferon gamma, and MCP-1 
concentrations according to the manufacturer’s instructions. In brief, 50 μ l of plasma per sample was mixed with 
50 μ l APC-conjugated beads and 50 μ l PE detection reagent. The mixtures were incubated at room temperature 
for 2 hours in the dark. Then samples were washed with washing buffer and centrifuged at 250 g for 5 min. The 
beads were resuspended in 300 μ l washing buffer and were assessed immediately with the Cyan-ADP analyser 
(Beckman Coulter). Cytokine concentrations were determined from a standard curve using the standards pro-
vided. Data were analysed with FCAP Array Analysis Software (v3, Soft Flow, Inc.).
Immunofluorescence staining and quantification of monocytes/macrophage and angiogenesis 
within the aortic wall. Six SRAs were randomly chosen from each group for immunofluorescence staining. 
6 μ m cryostat sections were cut for immunofluorescence staining. Briefly, sections were fixed in cold acetone at 
− 20 °C for 20 min and then blocked with 5% normal goat serum in PBS containing 0.5% BSA and 0.1% Triton 
X-100 for 60 min at room temperature. Sections were incubated with rat anti-MOMA-2 (Abcam, ab33451) or 
rat anti-CD31 (MEC 13.3; Santa Cruz, sc-18916) antibodies at a dilution of 1:100 in PBS containing 0.5% BSA 
overnight at 4 °C. Rat IgG (Sigma I4131) was used as isotype control. After washing, samples were incubated with 
Alexa fluor 488-conjugated anti-rat IgG secondary antibody at a dilution of 1:200 for 60 min at room temperature. 
Cell nuclei were labelled by DAPI (Sigma-Aldrich). Slides were mounted with water based mounting medium 
and covered with a coverslip. Five images were captured from randomly chosen microscopic field of each sec-
tion at x200 total magnification by a Zeiss fluorescence microscope (Zeiss). For each image, the total tissue area 
and the MOMA-2 or CD31 stained positive area were measured with ImageJ software (V1.4d, NIH). Data were 
expressed as percentage of positive staining area per analysed area. Good intra- and inter-observer reproducibility 
was demonstrated with mean differences of 0.063% (95% limits of agreement: − 0.471–0.346; n = 12) and 0.075% 
(95% limits of agreement: − 0.926–1.080; n = 12), respectively.
Statistical analysis. D’Agostino Pearson test was used to test the distribution of all data. Normally dis-
tributed continuous data were expressed as mean ± SEM and compared between groups using Student’s t-test. 
Non-normally distributed data were expressed as median (interquartile range) and compared between groups 
using Mann-Whitney U-test. Data was analysed using GraphPad Prism 6 software (San Diego, CA, USA). Survival 
free from aneurysm rupture was assessed using Kaplan-Meier analysis and compared between groups using 
log-rank test. Pearson correlation coefficient test was used to assess the relationship between pro-inflammatory 
cytokine MCP-1 concentrations in aortic tissue and maximum SRA aortic diameters. A value of p < 0.05 was 
considered statistical significant.
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